Feasibility and safety of robotic-assisted total pancreatectomy: a pilot western series

Emanuele F. Kauffmann1 · Niccolò Napoli1 · Valerio Genovese1 · Michael Ginesini1 · Cesare Gianfaldoni1 · Fabio Vistoli1 · Gabriella Amorese2 · Ugo Boggi1

Received: 13 April 2021 / Accepted: 3 May 2021 / Published online: 19 May 2021 © The Author(s) 2021

Abstract
This study was designed to demonstrate non-inferiority of robot-assisted total pancreatectomy (RATP) to open total pancreatectomy (OPT) based on an intention-to-treat analysis, having occurrence of severe post-operative complications (SPC) as primary study endpoint. The two groups were matched (2:1) by propensity scores. Assuming a rate of SPC of 22.5% (non-inferiority margin: 15%; α: 0.05; β: 0.20; power: 80%), a total of 25 patients were required per group. During the study period (October 2008–December 2019), 209 patients received a total pancreatectomy. After application of exclusion and inclusion criteria, matched groups were extracted from an overall cohort of 132 patients (OPT: 107; RATP: 25). Before matching, the two groups were different with respect to prevalence of cardiac disease (24.3% versus 4.0%; p = 0.03), presence of jaundice (45.8% versus 12.0%; p = 0.002), presence of a biliary drainage (23.4% versus 0; p = 0.004), history of weight loss (28.0% versus 8.0%; p = 0.04), and vein involvement (55.1% versus 28.0%) (p = 0.03). After matching, the two groups (OTP: 50; RATP: 25) were well balanced. Regarding primary study endpoint, SPC developed in 13 patients (26.0%) after OTP and in 6 patients (24.0%) after RATP (p = 0.85). Regarding secondary study endpoints, RATP was associated with longer median operating times [475 (408.8–582.5) versus 585 min (525–637.5) p = 0.003]. After a median follow-up time of 23.7 months (10.4–71), overall survival time [22.6 (11.2–81.2) versus NA (27.3–NA) p = 0.006] and cancer-specific survival [22.6 (11.2–NA) versus NA (27.3–NA) p = 0.02] were improved in patients undergoing RATP. In carefully selected patients, robot-assisted total pancreatectomy is non-inferior to open total pancreatectomy regarding occurrence of severe post-operative complications.

Keywords Total pancreatectomy · Robotic total pancreatectomy · Robotic pancreatectomy · Robotic pancreatoduodenectomy · Surgical complications · Pancreatic cancer

Introduction
Total pancreatectomy was initially introduced to avoid the consequences of post-operative pancreatic fistula [1] and to improve surgical radicality [2]. The procedure became very popular in the late ‘70s and in the ‘80s, when over 40% of pancreatic resections were total pancreatectomies [3]. Enthusiasm, however, was soon mitigated by the evidence that total pancreatectomy neither reduced post-operative mortality [4] nor improved long-term survival [5]. Additionally, total pancreatectomy decreases quality of life, by creating full exocrine and endocrine insufficiency [6]. Currently, total pancreatectomy is performed selectively, in approximately 6% of the patients who receive a pancreatic resection [7]. In the majority of these patients, total pancreatectomy is required due to widespread involvement of the gland [8] or in case of locally advanced tumors requiring arterial resection and reconstruction [9]. These indications may not apply well to a minimally invasive approach. However, total pancreatectomy may also be required in patients with positive frozen section histology of pancreatic neck margin during pancreatoduodenectomy [10], multifocal endocrine tumors [11, 12], metastatic tumors [13], main duct intraductal papillary mucinous tumors [12, 14], premalignant lesions in patients with history of familial pancreatic
cancer [8], extremely soft pancreatic remnants and small ducts in patients with right-sided tumors [15], and chronic pancreatitis with refractory pain [16]. In these patients, a minimally invasive approach may be an appealing alternative to open surgery. However, laparoscopic total pancreatectomy continues to be performed rarely. Barriers to wider adoption of laparoscopy for total pancreatectomy are likely to include the need for extensive retroperitoneal dissection while handling a rather bulky specimen in a deep space, the need to construct two digestive anastomoses, and the necessity to introduce several adaptations in respect to well-established open surgical techniques. At least in theory, the use of robotic assistance could facilitate the performance of all these tasks and could result in faster and safer implementation of minimally invasive total pancreatectomy.

In 2015, we reported on 11 cases of robotic-assisted total pancreatectomy (RATP) in the context of a matched analysis with open total pancreatectomy (OTP). In this study, we showed that RATP was feasible, despite longer operating times, and was associated with reduced blood loss, earlier achievement of independent mobility, earlier recovery of bowel functions, and improved pain scores with proportionally reduced need for post-operative analgesic therapy [17].

We herein present on 25 RATPs and provide a further comparison with contemporary cohort of OTPs matched by propensity scores.

Methods

This study was designed and reported according to the STROBE guidelines [18], and was approved by the Institutional Review Board of our hospital. Data were extracted from a prospectively maintained database and were analyzed retrospectively.

This study includes patients operated between October 2008 and December 2019 at the Division of General and Transplant Surgery of the Azienda Ospedaliera Universitaria Pisana, serving as the main referral center for surgical treatment of pancreatic diseases for approximately 1.2 million people, and receiving also patient referrals from all over Italy. At our Institution, the first da Vinci Surgical System (Intuitive Surgical®, Sunnyvale, California, US) was installed in the year 2000.

Selection criteria for RATP were: general suitability for laparoscopic surgery, absence of history of previous major upper abdominal surgery (e.g., partial or total gastrectomy, or major hepatectomy), body mass index (BMI) ≤ 35 kg/m², a preoperative diagnosis requiring total pancreatectomy while excluding locally advanced malignancy, and timely availability of the robot. Vein involvement without severe stenosis or obstruction was not considered an absolute contraindication.

To confirm that RATP is feasible and to further investigate its possible advantages, a control group was selected from a contemporary cohort of patients undergoing total pancreatectomy by an open approach.

To minimize bias from nonrandomized treatment assignment, RATP cases were matched with a 2:1 ratio with OTP controls using a conservative caliper width of 0.2. The following parameters, known to predict post-operative outcomes in total pancreatectomy, were used: age [19, 20], gender [19, 20], body mass index [21], history of cardiac disease [22], American Society of Anesthesiologists (ASA) score [23, 24], history of weight loss [25], presence of jaundice [26], preoperative biliary drainage [27, 28], and involvement of the superior mesenteric/portal vein [23, 28].

The technique for RATP was previously described in detailed [17], and is shown in the attached video (supplementary material 1), but some important tips and tricks deserve a specific comment. First, in case of concurrent splenectomy, the left gastric vein should be preserved to avoid gastric congestion [29]. Second, when the spleen can be spared, preservation of the splenic vessels (alike in a Kimura procedure) is preferable [30] to avoid sinistral portal hypertension, but the lymph nodes located along the splenic vessels should be removed to ensure adequate staging [31]. Third, the first duodenal portion (or gastric antrum) should not be divided until the distal pancreas are fully mobilized to prevent retraction of the stomach in the left upper abdominal quadrant [17]. Fourth, during retroperitoneal dissection, large lymphatics should be sealed by ligatures or clips [32] to reduce incidence and severity of prolonged lymphatic drainage, including chyle leak [33].

In patients requiring vein resection and reconstruction, the vascular procedure was classified according to the International Study Group of Pancreatic Surgery [34].

Definition of study outcomes

Post-operative complications were graded using the Clavien–Dindo classification [35], and were considered severe when ≥ 3. The comprehensive complication index (CCI) was also calculated [36]. Delayed gastric emptying (DGE) [37] and postpancreatectomy hemorrhage (PPH) [38] were defined according to the International Study Group on Pancreatic Surgery. Post-operative death, was defined as any death occurring during the initial hospital stay or the first 90 days after surgery.

Overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CCS) were defined according to DATECAN (Definition for Assessment of Time-to-event End-points in CANcer trials) [39].
Primary and secondary study endpoints

The primary endpoint of this study was the rate of severe post-operative complications.

Secondary endpoints were: operating time, length of hospital stay, proportion of patients with grade 1–2 post-operative complications, CCI score, proportion of patients receiving blood transfusions, incidence and severity of PPH, incidence and severity of DGE, need for repeat surgery at 90 days, number of examined lymph nodes, proportion of patients receiving adjuvant chemotherapy, proportion of patients completing adjuvant chemotherapy, OS, DFS, and CSS.

Follow-up

After hospital discharge patients were seen in our outpatient clinic at least once a month during the first 3 months and every 3 months thereafter. A computed tomography scan was obtained every 6 months for the first 5 years, and yearly thereafter.

Statistical analysis

The study was designed to demonstrate non-inferiority of RATP to OPT in terms of occurrence severe post-operative complications based on an intention-to-treat analysis that keeps in the minimally invasive group the patients who required conversion to open surgery. An overall rate of 22.5% [22] was assumed for both groups, and the non-inferiority margin was set at 15%. In addition, the $\alpha$ was set at 0.05 and $\beta$ at 0.20, yielding a power of 80%. Therefore, to demonstrate non-inferiority of experimental (i.e., RATP) and standard (i.e., OTP) a total of 50 patients would be required to be 80% certain that the upper limit of a one-sided 97.5%CI—or equivalently a two-sided 95%CI—would exclude a difference in favor of OPT exceeding 15%.

Quantitative variables are presented as mean ± SD if normally distributed, or as median and interquartile range (IQR) if not. Categorical variables are expressed as frequencies, percentages, and rates. Kolmogorov–Smirnov test was used to assess normality distribution. Chi-square test was used to evaluate the presence of an association between surgical technique (OPD and RPD) and outcome.

All statistical analyses were carried out with JMP® 15.2.0 software package for Mac, Copyright© SAS Institute Inc., SAS campus Drive, Cary, NC, USA and R Package, R Core Team (2014): A language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna AT using Matching, MatchIt and TrialSize as packages.

Results

During the study period, a total of 209 patients underwent total pancreatectomy. After exclusion of 75 patients with concurrent arterial resection and 2 patients operated laparoscopically, there were 132 patients who received either an OTP ($n = 107$) or a RATP ($n = 25$). After matching, there were 50 OTP and 25 RATP (Fig. 1).

Before matching, the two groups differed in prevalence of cardiac disease (1; 4.0% versus 26; 24.3%) ($p = 0.03$), presence of jaundice (3; 12.0% versus 49; 45.8%) ($p = 0.002$), need for a biliary drainage (0 versus 25; 23.4%) ($p = 0.004$), history of weight loss (2; 8.0% versus 30; 28.0%) ($p = 0.04$), and vein involvement (7; 28.0% versus 59; 55.1%) ($p = 0.03$).

The matching process identified 75 patients, including 50 OTPs and 25 RATPs. As shown in Table 1, the two groups were fully matched for all baseline characteristics.

Fifteen RATPs (60%) were two-stage procedures (i.e., resection was extended to achieve a radical resection following positive frozen section histology at the neck margin). The proportion of two-stage procedures was similar in the two groups (60% vs 48.6%; $p = 0.30$).

Conversion to open surgery was required in two RATPs (8.0%). In both patients, conversion occurred under elective conditions because of unanticipated need for multivisceral
resection and chronic inflammation of peripancreatic tissues precluding safe dissection, respectively.

As shown in Table 2, RATPs was associated with longer operating time, higher rates of pylorus preservation, and lower rates of type 3 vein reconstruction in both unmatched and matched cohorts. Before matching differences were also noted regarding the need for vein resection. Looking specifically at operative parameters in matched cohorts, it is worth to note that the main difference between the two groups was longer median operating time in RATPs (585; 525–637.5 min versus 475; 408.8–582.5 min) (p = 0.0003). Differences in rates of pylorus preservation (23; 92.0% versus 35; 70.0%) (p = 0.04), and rate of type 3 venous reconstruction (3; 12.0% versus 18; 36.0%) (p = 0.03) were also noted.

Regarding the main endpoint of this study, as shown in Table 3, severe post-operative complications developed in 6 patients (24.0%) after RATP and in 13 patients (26.0%) after OTP (p = 0.85). Overall, there were 9 post-operative deaths (6.8%) in unmatched cohorts, and 5 (6.7%) in matched cohorts with 1 death after RATP (4.0%) and 4 deaths after OTP (8.0%) (p = 0.66).

Regarding the secondary endpoints of this study, differences in operating times were already presented. Concerning the remaining parameters, results achieved in the two study groups were equivalent with respect to length of hospital stay, proportion of patients with grade 1–2 post-operative complications, CCI score, proportion of patients receiving blood transfusions, incidence and severity of PPH, incidence and severity of DGE, need for repeat surgery at 90 days, number of examined lymph nodes, proportion of patients receiving adjuvant chemotherapy, proportion of patients completing adjuvant chemotherapy, and DFS (Tables 3, 4, and 5). RATPs was instead associated with longer overall OS and CSS (Fig. 2).

Details on histology of resected specimens are reported and oncologic follow-up are reported in Tables 4 and 5, respectively.

Discussion

Total pancreatectomy is certainly a major procedure that, even when successful, imposes major consequences on patients resulting in impaired quality of life [6, 19]. Therefore, patients requiring a total pancreatectomy could not be considered good candidates for a minimally invasive procedure, which is typically performed to enhance patients’ rehabilitation [40, 41], improve quality of life [42, 43], and minimize the impact of surgery on body image [44, 45]. On the other hand, in properly selected patients, total pancreatectomy could be conveniently performed through a minimally invasive approach, because it does not require a pancreatic Anastomosis and therefore avoids post-operative complications. 

Table 1 Baseline characteristics before and after 2:1 matching by propensity scores

|                          | Before matching |                      | After matching |                      |
|--------------------------|-----------------|----------------------|----------------|----------------------|
|                          | All | RATP | OTP | p   | All | RATP | OTP | p   |
| Number of patients       | 132 (100%) | 25 (18.9%) | 107 (81.1%) | NA | 75 (100%) | 25 (33%) | 50 (66.7%) | NA |
| Age: years; mean ± SD    | 67.2 ± 10 | 66.7 ± 8.9 | 67.1 ± 1 | 0.79 | 67.5 ± 9.5 | 67.7 ± 8.9 | 67.4 ± 9.9 | 0.9 |
| Female gender; number (%)| 52 (39.4%) | 12 (48%) | 40 (37.4%) | 0.33 | 33 (44%) | 12 (48%) | 21 (42%) | 0.62 |
| BMI; kg/m²; mean ± SD    | 24.6 ± 3.3 | 23.7 ± 2.2 | 24.8 ± 0.3 | 0.17 | 23.8 ± 2.5 | 23.7 ± 2.2 | 23.8 ± 2.6 | 0.85 |
| ASA score; median (IQR)  | 3 (2–3) | 3 (2–3) | 3 (3–3) | 0.15 | 3 (2–3) | 3 (2–3) | 3 (2–3) | 0.71 |
| Cardiac disease; number (%)| 27 (20.5%) | 1 (4%) | 26 (24.3%) | 0.03 | 6 (8%) | 1 (4%) | 5 (10%) | 0.66 |
| COPD; number (%)         | 15 (11.4%) | 3 (12%) | 12 (11.2%) | 1 | 7 (9.3%) | 3 (12%) | 4 (8%) | 0.68 |
| Hypertension; number (%) | 65 (49.2%) | 14 (56%) | 51 (47.7%) | 0.45 | 35 (46.7%) | 14 (56%) | 21 (42%) | 0.25 |
| Diabetes mellitus; number (%)| 49 (37.1%) | 10 (40%) | 39 (36.5%) | 0.74 | 26 (34.7%) | 10 (40%) | 16 (32%) | 0.49 |
| Jaundice; number (%)     | 52 (39.4%) | 3 (12%) | 49 (45.8%) | 0.002 | 12 (16%) | 3 (12%) | 9 (18%) | 0.74 |
| Abdominal pain; number (%)| 66 (50%) | 12 (48%) | 54 (50.5%) | 0.82 | 35 (46.7%) | 12 (48%) | 23 (46%) | 0.87 |
| Duodenal obstruction; number (%)| 9 (6.8%) | 2 (8%) | 7 (6.5%) | 0.68 | 5 (6.7%) | 2 (8%) | 3 (6%) | 1 |
| Weight loss; number (%)  | 32 (24.2%) | 2 (8%) | 30 (28%) | 0.04 | 100 (13.3%) | 2 (8%) | 8 (16%) | 0.48 |
| Vein involvement; number (%)| 66 (50%) | 7 (28%) | 59 (55.1%) | 0.03 | 31 (41.3%) | 7 (28%) | 24 (48%) | 0.10 |
| Biliary drainage, number (%)| 25 (18.9%) | 0 (0%) | 25 (23.4%) | 0.004 | 0 (0%) | 0 (0%) | 0 (0%) | 0 |
| Previous abdominal surgery; number (%)| 79 (59.8%) | 15 (60%) | 64 (59.8%) | 0.99 | 46 (61.3%) | 15 (60%) | 31 (62%) | 1 |
| Preoperative chemotherapy; number (%)| 9 (6.8%) | 0 (0%) | 9 (8.4%) | 0.21 | 3 (4%) | 0 (0%) | 3 (6%) | 0.55 |

Statistically significant p values are highlighted in bold

BMI body mass index, ASA American Society of Anesthesiologists, COPD chronic obstructive pulmonary disease
pancreatic fistula by definition. Additionally, a minimally invasive approach has the potential to reduce some complications that occur frequently after total pancreatectomy such as DGE [19], pulmonary complications [19], abdominal infections [46], and surgical site infections [23].

RATP is a surgical innovation, since it is a “modified surgical procedure that differs from currently accepted local practice, the outcomes of which have not been described, and which may entail risk to the patient” [47]. When classified according to the Idea, Development, Exploration, Assessment, Long Term Study (IDEAL) recommendations [48], RATP has nearly completed stage 2a (development) and is moving forward in stage 2b (exploration). Stage 2a refers to a procedure that may still require technical refinements and that has been performed only in small groups of patients. Stage 2b begins when the main technical aspects of the procedure have been fixed, but experience is still limited. In both stages, outcomes should be recorded prospectively to ensure that all adverse events are captured. Reporting in stage 2a includes selection criteria, proportion of eligible patients, technical modifications, clinical outcomes, and specific complications. Reporting in stage 2b should mostly consist of clinical studies providing preparatory information for subsequent major randomized clinical studies [48].

According to this background, this study provides the highest possible level of evidence for a procedure in stage 2a–2b in the IDEAL framework (i.e., RATP), by assessing safety (i.e., incidence of severe post-operative complications) in the context of a propensity score matched comparison with the current treatment standard (i.e., OTP). Our data show that RATP is non-inferior to OTP with respect to occurrence of SPC. The relevance of this piece of information is enhanced by the fact that our results were achieved in the first 25 RATPs. Despite the learning curve

| Table 2: Operative time and procedures | Before matching | After matching |
|---------------------------------------|----------------|---------------|
|                                       | All          | RATP          | OTP          | All          | RATP          | OTP          | p      |
| Number of patients                    | 132 (100%)   | 25 (18.9%)    | 107 (81.1%)  | 75 (100%)    | 25 (33.3%)   | 50 (66.7%)   | NA    |
| Operative time; minutes; median (IQR) | 520 (445–610)| 585 (525–637.5)| 500 (430–600)| 520 (445–605)| 585 (525–637.5)| 475 (408.8–582.5)| **0.002** |
| En-bloc splenectomy (%)               | 107 (81.1%)  | 18 (72%)      | 89 (83.2%)   | 60 (80%)     | 18 (72%)     | 42 (84%)     | 0.20  |
| Preservation of spleen and splenic vessels; number (%) | 25 (18.9%) | 7 (28%) | 18 (16.8%) | 15 (20%) | 7 (28%) | 8 (16%) | 0.22 |
| Pylorus preservation; number (%)     | 91 (68.9%)   | 23 (92%)      | 68 (63.6%)   | 58 (77.3%)   | 23 (92%)     | 35 (70%)     | **0.007** |
| Total gastrectomy; number (%)        | 6 (4.5%)     | 0 (0%)        | 6 (5.6%)     | 2 (2.7%)     | 0 (0%)       | 2 (4%)       | 0.59  |
| Multivisceral resection; number (%)  | 27 (20.5%)   | 2 (8%)        | 25 (23.4%)   | 16 (21.3%)   | 2 (8%)       | 14 (28%)     | 0.1   |
| Vein resection; number (%)           | 66 (50%)     | 7 (28%)       | 59 (55.1%)   | 31 (41.3%)   | 7 (28%)      | 24 (48%)     | **0.03** |
| Superior mesenteric vein resection; number (%) | 11 (8.3%) | 0 (0%) | 11 (10.3%) | 5 (6.7%) | 0 (0%) | 5 (10%) | 0.12 |
| Portal vein resection; number (%)    | 3 (2.3%)     | 2 (8%)        | 1 (0.9%)     | 2 (2.7%)     | 2 (8%)       | 0 (0%)       | 0.09  |
| Mesenteric-portal confluence resection; number (%) | 52 (39.4%) | 5 (20%) | 47 (43.9%) | 24 (32%) | 5 (20%) | 19 (38%) | **0.03** |
| Type 3 vein reconstruction; number (%) | 48 (36.4%) | 3 (12%) | 45 (42.1%) | 21 (28%) | 3 (12%) | 18 (36%) | **0.03** |
| Type 4 vein reconstruction; number (%) | 18 (13.6%) | 4 (16%) | 14 (13.1%) | 10 (13.3%) | 4 (16%) | 6 (12%) | 0.72 |

Statistically significant p values are highlighted in bold.
for robotic total pancreatectomy has not been defined yet, and could be influenced by contemporary volume of other types of pancreatic resections, it is reasonable to accept that with further experience, we should be able to reduce our operating times. As longer operating times were one of the main differences between RATP and OTP, and duration of surgery exceeding 420 min is a strong prognostic factor for the development of post-operative complications [19], future results could be more favorable.

Table 3  Post-operative results

|                                   | Before matching | After matching |
|-----------------------------------|-----------------|---------------|
|                                   | All            | RATP          | OTP           | p   | All            | RATP          | OTP           | p   |
| Number of patients                | 132 (100%)     | 25 (18.9%)   | 107 (81.1%)  | NA  | 75 (100%)     | 25 (33%)     | 50 (66.7%)  | NA  |
| Length of stay; median (IQR); days| 20 (15–30)     | 22 (14.5–30.5) | 19 (15–30)  | 0.54 | 20 (14–28)  | 22 (14.5–30.5) | 18 (14–28)  | 0.19 |
| Patients receiving blood transfusions; number (%) | 40 (30.3%) | 5 (20%) | 35 (32.7%) | 0.21 | 24 (32%) | 5 (20%) | 19 (38%) | 0.12 |
| Patients without complications; number (%) | 42 (31.8%) | 7 (28%) | 35 (32.7%) | 0.65 | 27 (36%) | 7 (28%) | 20 (40%) | 0.31 |
| Patients with grade I complications; number (%) | 3 (2.3%) | 0 (0%) | 3 (2.8%) | 1 | 1 (1.3%) | 0 (0%) | 1 (2%) | 1 |
| Patients with grade II complications; number (%) | 50 (37.9%) | 12 (48%) | 38 (35.5%) | 0.25 | 28 (37.3%) | 12 (48%) | 16 (32%) | 0.18 |
| Patients with grade IIIa complications; number (%) | 13 (9.8%) | 4 (16%) | 9 (8.4%) | 0.27 | 7 (9.3%) | 4 (16%) | 3 (6%) | 0.21 |
| Patients with grade IIIb complications; number (%) | 6 (4.5%) | 0 (0%) | 6 (5.6%) | 0.59 | 4 (5.3%) | 0 (0%) | 4 (8%) | 0.29 |
| Patients with grade IVa complications; number (%) | 8 (6.1%) | 1 (4%) | 7 (6.5%) | 1 | 3 (4%) | 1 (4%) | 2 (4%) | 1 |
| Patients with grade IVb complications; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Patients with grade V complications; number (%) | 9 (6.8%) | 1 (4%) | 8 (7.5%) | 1 | 5 (6.7%) | 1 (4%) | 4 (8%) | 0.66 |
| Patients with severe complications (≥ 3a); number (%) | 37 (28%) | 6 (24%) | 31 (29%) | 0.62 | 19 (25.3%) | 6 (24%) | 13 (26%) | 0.85 |
| Comprehensive Complication Index; median (IQR) | 22.6 (0–33.7) | 20.9 (0–32.5) | 22.6 (0–36.2) | 0.76 | 20.9 (0–29.6) | 20.9 (0–32.5) | 20.9 (0–39.6) | 0.72 |
| Post-pancreatectomy hemorrhage; number (%) | 10 (7.6%) | 2 (8%) | 8 (7.5%) | 1 | 7 (9.3%) | 2 (8%) | 5 (10%) | 1 |
| Grade A; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Grade B; number (%) | 4 (3%) | 1 (4%) | 3 (2.8%) | 0.57 | 3 (4%) | 1 (4%) | 2 (4%) | 1 |
| Grade C; number (%) | 5 (3.8%) | 1 (4%) | 4 (3.7%) | 1 | 4 (5.3%) | 1 (4%) | 3 (6%) | 1 |
| Delayed gastric emptying; number (%) | 14 (10.6%) | 6 (24%) | 8 (7.5%) | 0.02 | 11 (14.7%) | 6 (24%) | 5 (10%) | 0.11 |
| Grade A; number (%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Grade B; number (%) | 11 (8.3%) | 4 (16%) | 7 (6.5%) | 0.22 | 8 (10.7%) | 4 (16%) | 4 (8%) | 0.43 |
| Grade C; number (%) | 3 (2.3%) | 2 (8%) | 1 (0.9%) | 0.09 | 3 (4%) | 2 (8%) | 1 (2%) | 0.26 |
| Biliary leak; number (%) | 3 (2.3%) | 0 (0%) | 3 (2.8%) | 1 | 1 (1.3%) | 0 (0%) | 1 (2%) | 1 |
| Enteric fistula; number (%) | 5 (3.8%) | 0 (0%) | 5 (4.5%) | 0.58 | 3 (4%) | 0 (0%) | 3 (6%) | 0.55 |
| Medical complications; number (%) | 71 (53.8%) | 11 (44%) | 60 (56.1%) | 0.28 | 35 (46.7%) | 11 (44%) | 24 (48%) | 0.74 |
| Repeat surgery at 90 days; number (%) | 17 (12.9%) | 2 (8%) | 15 (14%) | 0.53 | 9 (12%) | 2 (8%) | 7 (14%) | 0.71 |

Statistically significant p value is highlighted in bold

Technical considerations

Despite total pancreatectomy is almost automatically associated with the concept of splenectomy, we could preserve the spleen along with the splenic vessels in 18 of 107 OTPs (16.8%) and in 7 of 25 (28.0%) RATPs. Other series have shown rates of spleen preservation ranging from 6.4 to 34% [19, 20].

In general, spleen preservation is considered to be important to reduce intraoperative bleeding [49], to
decrease the risk of thromboembolic events [50], and to prevent overwhelming post splenectomy spesis [51]. In patients diagnosed with pancreatic tumors, splenectomy does not improve oncologic radicality, mostly due to the rare occurrence of lymph-node metastasis at the splenic hilum [52, 53], and was instead shown to reduce long-term

Table 4 Pathology of resected specimens

| Number of patients | Before matching | After matching | p  |
|--------------------|-----------------|---------------|----|
|                    | All             | RATP          | OTP | NA      | All             | RATP          | OTP | NA      |
| Tumor types        |                 |               |     |         |                 |               |     |         |
| Pancreatic ductal adenocarcinoma; number (%) | 45 (34.1%) | 5 (20%) | 40 (37.4%) | 0.10 | 20 (26.7%) | 5 (20%) | 15 (30%) | 0.42 |
| Malignant IPMN; number (%) | 47 (35.6%) | 11 (44%) | 36 (33.6%) | 0.33 | 26 (34.7%) | 11 (44%) | 15 (30%) | 0.23 |
| IPMN; number (%) | 19 (14.4%) | 7 (28%) | 12 (11.2%) | 0.03 | 17 (22.7%) | 7 (28%) | 10 (20%) | 0.44 |
| Ampullary carcinoma; number (%) | 2 (1.5%) | 0 (0%) | 2 (1.9%) | 1 | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Duodenal adenocarcinoma; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 1 (1.3%) | 0 (0%) | 1 (2%) | 1 |
| Acinar cell carcinoma; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Gastric cancer; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 0 (0%) | 0 (0%) | 0 (0%) | NA |
| Metastasis from renal cell carcinoma; number (%) | 6 (4.5%) | 1 (4%) | 5 (4.7%) | 1 | 5 (6.7%) | 1 (4%) | 4 (8%) | 0.66 |
| Chronic pancreatitis; number (%) | 6 (4.5%) | 1 (4%) | 5 (4.7%) | 1 | 3 (4%) | 1 (4%) | 2 (4%) | 1 |
| Neuroendocrine tumor; number (%) | 3 (2.3%) | 0 (0%) | 3 (2.8%) | 1 | 2 (2.7%) | 0 (0%) | 2 (4%) | 1 |
| Lymphoma; number (%) | 1 (0.8%) | 0 (0%) | 1 (0.9%) | 1 | 1 (1.3%) | 0 (0%) | 1 (2%) | 1 |
| Number of examined lymph nodes; mean ± SD | 63.3 ± 27.2 | 66.1 ± 5.5 | 62.6 ± 2.6 | 0.57 | 61 ± 25.8 | 66.1 ± 5.5 | 58.4 ± 24 | 0.26 |
| Number of positive lymph nodes; median (IQR) | 1 (0–4) | 0 (0–1) | 1 (0–5) | 0.02 | 0 (0–3) | 0 (0–1) | 0 (0–5.3) | 0.25 |
| Patients with positive marginsa; number (%) | 30 (30.9%) | 4 (25%) | 26 (32.1%) | 0.77 | 14 (29.8%) | 4 (25%) | 10 (32.3%) | 0.74 |
| Patients with confirmed vascular invasion; number (%) | 42 (63.6%) | 4 (57.1%) | 38 (64.4%) | 0.70 | 22 (71%) | 4 (57.1%) | 18 (75%) | 0.38 |
| Length of resected vein segment; cm; mean ± SD | 3.1 ± 1.1 | 2.1 ± 0.5 | 3.2 ± 1.1 | 0.009 | 2.8 ± 1 | 2.1 ± 0.5 | 2.9 ± 1 | 0.04 |

Statistically significant p values are highlighted in bold
IPMN intraductal papillary mucinous neoplasm
aMargins are assessed circumferentially and at 1 mm

Table 5 Oncologic follow-up in patients with pancreatic cancer and malignant IPMN (not including post-operative deaths)

| Before matching | After matching | p  |
|-----------------|---------------|----|
| Patients number (%) | 83 (62.9%) | 15 (60%) | 68 (63.6%) | 0.74 | 41 (54.7%) | 15 (60%) | 26 (52%) | 0.51 |
| Patients receiving adjuvant chemotherapy; number (%) | 57 (60.6%) | 7 (46.7%) | 50 (63.3%) | 0.23 | 26 (56.5%) | 7 (46.7%) | 19 (61%) | 0.35 |
| Patients completing adjuvant chemotherapy; number (%) | 43 (62.3%) | 9 (75%) | 34 (59.7%) | 0.32 | 22 (66.7%) | 9 (75%) | 13 (61.9%) | 0.44 |
| Overall survival; months; median (IQR) | 27.3 (10.2–NA) | NA (27.3–NA) | 23.3 (9.8–NA) | 0.004 | 43.5 (12.2–NA) | NA (27.3-NA) | 22.6 (11.2–81.2) | 0.006 |
| Cancer specific survival; months; median (IQR) | 27.3 (10.2–NA) | NA (27.3–NA) | 23.3 (9.8–NA) | 0.006 | NA (12.2–NA) | NA (27.3-NA) | 22.6 (11.2-NA) | 0.02 |
| Disease-free survival; months; median (IQR) | 9.1 (4.5–15.5) | 7.6 (7.6–7.6) | 10.1 (4–16) | 0.63 | 10.5 (5.5–19.07) | 7.6 (7.6–7.6) | 11.2 (5.5–19.7) | 0.58 |

Statistically significant p values are highlighted in bold
RTPD robot-assisted total pancreatectoduodenectomy, OTP open total pancreatectoduodenectomy
survival [54] as already shown for the stomach [55] and the colon [56]. Finally, several in-vitro studies have demonstrated that the spleen plays in antitumor immune response and that splenectomy could facilitate development of distant metastasis [57, 58]. The robotic approach is known to facilitate spleen preservation during distal pancreatectomy, especially using the Kimura technique [59]. Although the spleen can be preserved also when sacrificing the splenic vessels, alike in a Warshaw procedure [60], we do not favor this approach in total pancreatectomy, since spleen supply would be left to a collateral circulation based on the left gastric vessels alone.

Considering that pylorus preservation is standard at our Institution [61], the higher ability to meet this goal with RATP (92.0% versus 70.0%) might mean that the robotic assistance improves the ability to preserve blood supply to the entire stomach when extensive retroperitoneal dissection is required.

In general, in patients requiring a vein resection, we favor segmental over tangential vein resection [62, 63]. In our hands and in the open setting, most of these procedures are currently type 3 vein resections/reconstructions. In RATP, we noted fewer direct, end-to-end, vein reconstructions with a proportional increase in type 4 procedures. This can be readily explained by the need to place the patient in reverse Trendelenburg position [17] and the relative inability to perform a Cattell–Braasch maneuver [64]. Due to these challenges, other groups prefer to pursue type 1-2 vein resections/reconstructions during minimally invasive procedures [65–68]. While all technical solutions are acceptable, provided that the opportunity of achieving a radical resection is not missed and vein patency is maintained, we recommend that surgeons should have a clear strategy for vein resection and reconstruction before embarking upon these procedures. These strategies might be different from those established in the open setting.

Length of hospital stay as a surrogate marker of early recovery

Most studies on minimally invasive procedures emphasize the importance of reduced length of hospital stay (versus open surgery). In some studies, especially from the United States, hospital stay may be very short, even in case of major procedures. In this study, we have not reported a short hospital stay after RATP. While achieving this goal is certainly important for stakeholders, it should be recognized that length of hospital stay may not be an objective parameter to evaluate the efficacy of surgical procedures, since it can be influenced by external factors, such as local and cultural attitudes [32]. Additionally, after total pancreatectomy, patients need to be trained to manage brittle diabetes before they can safely leave the hospital [69]. Finally, patients living far from hospital may feel unsecure if discharged too early, and may not accept this decision. We therefore suggest the use of more objective parameters, such as time to functional recovery [70], to show efficacy of post-operative recovery in surgical procedures.

Other reports on RATP

An analysis of current literature demonstrates only few case reports [12, 71, 72] and small series [12, 14, 17, 46, 73] reporting on either laparoscopic total pancreatectomy or RATP. Excluding our previous study [17], there is only one additional study comparing matched cohorts of RATP and OTP. In this study, Weng and co-workers report on 15 RATP and 78 OTP performed over a period of slightly more than
4 years at a Chinese center performing an average over 1000 pancreatic resections per year [46]. In unmatched cohorts, the two groups differed in BMI (lower in RATP), incidence of vascular involvement (less frequent in RATP), presence of variations in arterial liver supply (less frequent in RATP), rate of spleen preservation (higher in RATP), median length of hospital stay (shorter in RATP), number of examined lymph nodes (lower in RATP), and operating time (shorter in RATP). After 1:1 matching by propensity scores all differences but shorter operating time in RATP disappeared. This study confirmed that RATP, in selected patients, is not associated with an increased risk of post-operative complications. Actually, these authors reported impressively low rates of SPC after either RATP (6.7%) or OTP (14.1%). These figures should be carefully interpreted as they refer to a follow-up of only 30 days and were achieved in the context of a patient population in which two-thirds of the patients were classified ≤ ASA 2. Additionally, it is not clear how this group could achieve shorter operating times in the robotic group, but their impressively high annual volumes of robotic pancreatic resections (approximately 300 procedures per year) reinforce the concept that with enough practice operating times can be significantly reduced. It is also worth to note that even if length of hospital stay was shorter in the robotic group (18 versus 20 days), these figures are similar to our results (22 versus 18 days). Also the rate of spleen preservation in the robotic group (26.7%) is similar to the one recorded in our series (28.0%), further reinforcing the concept that robotic assistance facilitates spleen preservation [46].

Study limitations

This study has several limitations. First, despite prospective collection of data, the retrospective analysis carries the inherent risk of hidden biases mostly related to patient selection. Second, despite reporting on one of the largest series of minimally invasive total pancreatectomies, the relatively small number of procedures may not be sufficient enough to depict the full spectrum and severity of complications occurring following RATPs. Third, this series of RATPs was performed at a single institution, thereby limiting the generalizability of the results.

Conclusions

In conclusion, despite the above-mentioned limitations, our data show that RATP in selected patients is non-inferior to OTP regarding occurrence of severe post-operative complications. Therefore, this study contributes to define the role of robotic assistance in very complex procedures, such as total pancreatectomy.

We wish to underscore that the 25 RATPs reported herein constitute approximately 6% of our experience with robotic pancreatic resections and < 2% of our overall volume of pancreatic resections during the study period. Reproducibility of our results in centers with lower volumes of activity remains to be established.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s13304-021-01079-3.

Author contributions Substantial contributions were made to the conception or design of the work (UB), the acquisition, analysis (EFK, NN, VG, MG, CG, FV, and GA), interpretation of data for the work (EFK, NN and UB), drafting of the work (GA, and UB) or revising it critically for important intellectual content (EFK, NN, MG, CG, FV, GA, and UB), and final approved of the version to be published (EFK, NN, VG, MG, CG, FV, GA, and UB). Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (EFK, NN, VG, MG, CG, FV, GA, and UB).

Funding  Open access funding provided by Università di Pisa within the CRUI-CARE Agreement. This research did not receive any specific grant from funding agencies in public, commercial, or non-profit sectors.

Availability of data and materials  All materials are available upon request.

Declarations

Conflict of interest  The authors declare they have no conflict of interest. No preregistration exists for the studies reported in this article.

Research involving human participants and/or animals  Not applicable.

Informed consent and ethical approval  The Institutional Review Board of the University of Pisa approved this study.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ross DE (1954) Cancer of the pancreas; a plea for total pancreatectomy. Am J Surg 87:20–33. https://doi.org/10.1016/0002-9610(54)90038-0
2. Porter MR (1958) Carcinoma of the pancreatico-duodenal area; operability and choice of procedure. Ann Surg 148:711–723.
3. Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F (1987) Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 206:366–373. https://doi.org/10.1097/00000658-198709000-00015

4. Bhayani NH, Miller JL, Ortenzi G, Kaifi JT, Kimchi ET, Staveley-O’Carroll KF, Gusani NJ (2014) Perioperative outcomes of pancreaticoduodenectomy compared to total pancreatectomy for neoplasia. J Gastrointest Surg 18:549–554. https://doi.org/10.1007/s11605-013-2393-0

5. Dallemagne B, de Oliveira AT, Lacerda CF, D’Agostino J, Merillat C, Breisch-Girbig D, Ceyhan GO, Büchler MW (2007) Indications and early outcomes of total pancreatectomy with and without spleen and pylorus preservation: a feasibility report. J Hepatobiliary Pancreat Surg 14(3):265–272. https://doi.org/10.1007/s00534-006-0359-3

6. Casadei R, Marchegiani G, Laterza M, Ricci C, Marrano N, Margiotta A, Minni F (2009) Total pancreatectomy: doing it with a minimally invasive approach. JOP 10:328–331

7. Konstantinidis IT, Dursun A, Zheng H, Wargo JA, Thayer SP, Fernandez-del Castillo C, Warshaw AL, Ferrone CR (2010) Metastatic tumors in the pancreas in the modern era. J Am Coll Surg 211:749–753. https://doi.org/10.1016/j.jamcollsurg.2010.08.017

8. Choi SH, Hwang HK, Kang CM, Yoon CI, Lee WJ (2012) Pylorus- and spleen-preserving total pancreatectoduodenectomy with resection of both whole spleenic vessels: feasibility and laparoscopic application to intraductal papillary mucin-producing tumors of the pancreas. Surg Endosc 26:2072–2077. https://doi.org/10.1007/s00464-011-2113-3

9. Balzano G, Maffi P, Nano R, Zerbi A, Venturini M, Melzi R, Micali A, Magistretti P, Scavini M, Castoldi R, Carvello M, Braga M, Del Maschio A, Secchi A, Staudacher C, Piemonti L (2013) Laparoscopic robot-assisted versus open total pancreatectomy: a case-matched study. Surg Endosc 29:1452–1432. https://doi.org/10.1007/s00464-014-3819-9

10. Boggi U, Palladino S, Massimetti G, Vistolì F, Caniglia F, De Leo N, Perrone V, Barbalollo L, Belluomini M, Signori S, Amorese G, Mosca F (2015) Laparoscopic robot-assisted versus open total pancreatectomy: a case-matched study. Surg Endosc 29:1452–1432. https://doi.org/10.1007/s00464-014-3819-9

11. Limongelli P, Bansi D, Thillainagaram A, Tait P, Jackson J, Habib NA, Williamson RC, Jiao LR (2007) Correlation between preoperative biliary drainage, bile duct contamination, and postoperative outcomes for pancreatic surgery. Surgery 142:313–318. https://doi.org/10.1016/j.surg.2007.04.022

12. Ramacciato G, Nigri G, Petrucciani N, Pinza AD, Ravaiolì M, Jovine E, Minni F, Grazi GL, Chiarelli P, Tisonne G, Napoli N, Boggi U (2016) Pancreatectomy with mesenteric and portal vein resection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann Surg Oncol 23:2028–2037. https://doi.org/10.1245/s10434-016-5123-5

13. Nakao A, Yamada S, Fujii T, Tanaka H, Oshima K, Oshima Y, Iede K, Kobayashi H, Kimura Y, Kodera Y (2018) Gastric venous congestion and bleeding in association with total pancreatectomy.
32. Boggi U, Signori S, De Lio N, Perrone VG, Talarico F (2004) Spleen-preserving total pancreatectomy with conservation of the spleen vessels: operative technique and possible indications. Pancreas 28(2):207–210. https://doi.org/10.1097/00006667-200403000-00013

33. Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, Geschwind HF, Kong, Hong O, Georgiades C, Schulick RD, Pavlik TM (2008) Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg 12:1915–1923. https://doi.org/10.1007/s11605-008-0619-3

34. Lamadé W, Friedrich C, Ulmer C, Basar T, Weiss H, Thon KP (2011) Impact of body image on patients’ attitude towards conventional, minimal invasive, and natural orifice surgery. Langenbecks Arch Surg 396:331–336. https://doi.org/10.1007/s00423-010-0669-3

35. Bonnetain F, Bonsing B, Conroy T et al (2014) Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANCer trials). Eur J Cancer 50:2983–2993. https://doi.org/10.1016/j.ejca.2014.07.011

36. Mikami DJ, Melvin WS, Murayama MJ, Murayama KM (2017) Impact of minimally invasive surgery on healthcare utilization, cost, and workplace absenteeism in patients with Incisional/Ventral Hernia (IVH). Surg Endosc 31:4412–4418. https://doi.org/10.1007/s00464-017-5488-y

37. Krimpfhej MJ, Reese SW, Chen X, Marchese M, Pucheril D, Cone E, Chou W, Tully KH, Kibiel AS, Urman RD, Chang SL, Kluth LA, Dagsupta P, Trinh QD (2021) Recovery from minimally invasive vs. open surgery in kidney cancer patients: opioid use and workplace absenteeism. Investig Clin Urol 62:56–64. https://doi.org/10.4111/icu.20200194
57. Higashijima J, Shimada M, Chikakiyo M, Miyatani T, Yoshikawa K, Nishioka M, Iwata T, Kurita N (2009) Effect of splenectomy on antitumor immune system in mice. Anticancer Res 29:385–393
58. Imai S, Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseeng CC, Kawabata K, Masai Y, Tobe T (1991) Effects of splenectomy on pulmonary metastasis and growth of SC42 carcinoma transplanted into mouse liver. J Surg Oncol 47:178–187. https://doi.org/10.1002/jso.2930470309
59. Esposito A, Casetti L, De Pastena M, Ramera M, Montagnini G, Landoni L, Bassi C, Salvia R (2020) Robotic spleen-preserving distal pancreatectomy: the Verona experience. Updates Surg. https://doi.org/10.1007/s13304-020-00731-8
60. Warshaw AL (1988) Conservation of the spleen with distal pancreatectomy. Arch Surg 123:550–553. https://doi.org/10.1001/archsurg.1988.014002900032004
61. Mosca F, Giulianotti PC, Balestracci T, Boggi U, Giardino D, Di Candio G, Rossi G, Fornaciari G (1994) Preservation of the pylorus in duodenopancreatectomy in pancreatic and periampullary carcinoma. Chir Ital 46:59–67
62. Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C, Amorese G, Mazzeto S, Cappelli C, Campiani D, Mosca F (2009) Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 146:869–881. https://doi.org/10.1016/j.surg.2009.04.029
63. Kaufmann EF, Napoli N, Menonona F, Vistoli F, Amorese G, Campiani D, Polina LE, Funel N, Cappelli C, Carmella D, Boggi U (2016) Robotic pancreateoduodenectomy with vascular resection. Langenbecks Arch Surg 401:1111–1122. https://doi.org/10.1007/s00423-016-1499-8
64. Muttillo EM, Felli E, Pessaux P (2020) Cattell-Braasch maneuver in pancreatic surgery. No need of venous graft for vascular resection. J Surg Oncol 122:1612–1615. https://doi.org/10.1002/jso.26180
65. Allan BJ, Novak SM, Hogg ME, Zeh HJ (2018) Robotic vascular resections during Whipple procedure. J Vis Surg 4:13. https://doi.org/10.21037/jovs.2017.12.15
66. Shyr BU, Chen SC, Shyr YM, Wang SE (2020) Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy. Surg Endosc 34:377–383. https://doi.org/10.1007/s00464-019-06779-x
67. Kendrick ML, Sclabas GM (2011) Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB 13:454–458. https://doi.org/10.1111/j.1477-2578.2011.00323.x
68. Khatkov IE, Izrailov RE, Khisamov AA, Tyutymnik PS, Fingerhut A (2017) Superior mesenteric-portal vein resection during laparoscopic pancreaticoduodenectomy. Surg Endosc 31:1488–1495. https://doi.org/10.1007/s00464-016-5115-3
69. Maker AV, Sheikh R, Bhagia V, Diabetes Control and Complications Trial (DCCT) Research Group (2017) Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia. Langenbecks Arch Surg 402:873–883. https://doi.org/10.1007/s00423-017-1603-8
70. de Rooij T, van Hilst J, Vogel JA, van Santvoort HC, de Boer MT, Boerma D, van den Boezem PB, Bonsing BA, Bosscha K, Coene PP, Daams F, van Dam RM, Dijkgraaf MG, van Eijk CH, Festen S, Gerhards MF, Groot Koerkamp B, Hagendoom J, van der Harst E, de Hingh IH, Dejong CH, Kazemier G, Klaase J, de Kleine RH, van Laarhoven CJ, Lips DJ, Luyer MD, Molenaaer I, Nieuwenhuijs VB, Patijn GA, Roos D, Scheepers JJ, van der Schelling GP, Steenvoorde P, Swijnenburg RJ, Wijsman JH, Abu Hilal M, Busch OR, Besselink MG, Dutch Pancreatic Cancer Group (2017) Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial. Trials 18:166. https://doi.org/10.1186/s13063-017-1892-9
71. Galvani CA, Rilo HR, Samame J, Gruessner RW (2013) First fully robotic total pancreatectomy combined with islet autotransplantation for the treatment of chronic pancreatitis: a case report. Pancreas 42:1188–1189. https://doi.org/10.1097/MPA.0b013e31827fe875
72. Marquez S, Marquez TT, Ikramuddin S, Kandaswamy R, Antanavicius G, Freeman ML, Hering BJ, Sutherland DE (2010) Laparoscopic and da Vinci robot-assisted total pancreaticoduodenectomy and intraportal islet autotransplantation: case report of a definitive minimally invasive treatment of chronic pancreatitis. Pancreas 39:1109−1111. https://doi.org/10.1097/MPA.0b013e3181df262c
73. Asbun HJ, Stauffer JA (2012) Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the accordion severity grading system. J Am Coll Surg 215:810−819. https://doi.org/10.1016/j.jamcollsurg.2012.08.006

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.